

Isabelle Ray-Coquard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8364959/publications.pdf>

Version: 2024-02-01

250
papers

22,061
citations

16791

66
h-index

11282

141
g-index

291
all docs

291
docs citations

291
times ranked

22680
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network. <i>Cancers</i> , 2022, 14, 354.	1.7	5
2	Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond. <i>Cancers</i> , 2022, 14, 1064.	1.7	25
3	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	1.7	3
4	The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF- β 2 and PD-L1 Pathways. <i>Frontiers in Oncology</i> , 2022, 12, 814169.	1.3	8
5	Molecular Mechanisms of Kaposi Sarcoma Development. <i>Cancers</i> , 2022, 14, 1869.	1.7	10
6	Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 1765-1772.	3.2	17
7	A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein β 2ig-h3. <i>Journal of Personalized Medicine</i> , 2022, 12, 623.	1.1	2
8	Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network. <i>Cancers</i> , 2022, 14, 2345.	1.7	4
9	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networksâ€™ Outcome?. <i>Cancers</i> , 2022, 14, 2620.	1.7	4
10	Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia. <i>PLoS ONE</i> , 2022, 17, e0257673.	1.1	7
11	Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 2.	0.1	0
12	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 127-143.	4.3	59
13	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103172.	2.0	8
14	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e82.	1.0	6
15	Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin. <i>Future Oncology</i> , 2021, 17, 9-19.	1.1	3
16	Molecular Characterization of Ovarian Yolk Sac Tumor (OYST). <i>Cancers</i> , 2021, 13, 220.	1.7	4
17	Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. <i>Lancet Haematology</i> , 2021, 8, e122-e134.	2.2	139
18	Bringing Onco-Innovation to Europeâ€™s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583.	1.7	13

#	ARTICLE	IF	CITATIONS
19	Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 267-276.	5.1	79
20	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
21	Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and Number. <i>Journal of Immunology</i> , 2021, 206, 2265-2270.	0.4	7
22	The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. <i>Biology</i> , 2021, 10, 305.	1.3	3
23	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
24	Gynecological sarcomas: literature review of 2020. <i>Current Opinion in Oncology</i> , 2021, 33, 345-350.	1.1	1
25	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021, 21, 631.	1.1	14
26	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	5.1	215
27	Importance of guidelines and networking for the management of rare gynecological cancers. <i>Current Opinion in Oncology</i> , 2021, 33, 442-446.	1.1	4
28	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	0.6	7
29	Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer. <i>Future Oncology</i> , 2021, 17, 2291-2304.	1.1	2
30	TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfILER Precision Medicine Trials. <i>Cancers</i> , 2021, 13, 3362.	1.7	6
31	Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database. <i>Cancers</i> , 2021, 13, 3515.	1.7	3
32	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 226-234.	0.6	58
33	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. <i>Gynecologic Oncology</i> , 2021, 163, 64-71.	0.6	3
34	RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, S71.	0.6	1
35	Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2021, 162, S26-S27.	0.6	18
36	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. <i>Gynecologic Oncology</i> , 2021, 163, 274-280.	0.6	59

#	ARTICLE	IF	CITATIONS
37	TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer. <i>Cancers</i> , 2021, 13, 4394.	1.7	6
38	Dedicated Program for Adolescent and Young Adults With Cancer: A Better Way to Inform About Sexual and Fertility Issues. <i>JCO Oncology Practice</i> , 2021, 17, OP.21.00452.	1.4	1
39	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	14
40	Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). <i>Gynecologic Oncology</i> , 2021, 163, 237-245.	0.6	30
41	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.	3.4	25
42	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	0.6	20
43	Genetic Analysis in Anal and Cervical Cancer: Exploratory Findings About Radioresistance in the ProfILER Database. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 515-520.	1.0	0
44	Concordance Between Tumor and Germline <i><i>BRCA</i></i> Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 917-923.	3.0	26
45	Rare DICER1 and Absent FOXL2 Mutations Characterize Ovarian Juvenile Granulosa Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2021, 45, 223-229.	2.1	15
46	Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. <i>Current Oncology Reports</i> , 2021, 23, 148.	1.8	7
47	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. <i>Cancers</i> , 2021, 13, 5756.	1.7	11
48	Endometrial cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 88.	18.1	155
49	Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade. <i>Bulletin Du Cancer</i> , 2021, 108, S5-S12.	0.6	3
50	Results of API-3 based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome09 study. <i>International Journal of Cancer</i> , 2020, 146, 413-423.	2.3	18
51	Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. <i>Oncologist</i> , 2020, 25, e109-e119.	1.9	13
52	Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	2.3	40
53	Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 172-182.	0.7	13
54	Assessing the performance of indicators during their life cycle: the mixed QUID method. <i>International Journal for Quality in Health Care</i> , 2020, 32, 12-19.	0.9	1

#	ARTICLE	IF	CITATIONS
55	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. <i>Gynecologic Oncology</i> , 2020, 156, 377-386.	0.6	14
56	Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1693-1699.	0.7	10
57	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy—A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020, 215, 1539-1548.	1.0	21
58	Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region. <i>European Journal of Cancer Care</i> , 2020, 29, e13313.	0.7	0
59	Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors. <i>JAMA Oncology</i> , 2020, 6, 1923.	3.4	27
60	Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?. <i>EBioMedicine</i> , 2020, 61, 103046.	2.7	7
61	Cancer screening and follow-up in general practice: A French nationwide cross-sectional study. <i>European Journal of General Practice</i> , 2020, 26, 95-101.	0.9	3
62	Detailed overview on rare malignant ovarian tumors. <i>Bulletin Du Cancer</i> , 2020, 107, 385-390.	0.6	11
63	Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). <i>Gynecologic Oncology</i> , 2020, 159, 256-263.	0.6	11
64	Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT). <i>Gynecologic Oncology</i> , 2020, 159, 129-135.	0.6	8
65	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. <i>Cancer Treatment Reviews</i> , 2020, 90, 102107.	3.4	21
66	PARP Inhibitor in Advanced Endometrial Carcinoma Beyond BRCA and Related Genetic Mutations. <i>JCO Precision Oncology</i> , 2020, 4, 1025-1026.	1.5	1
67	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	0.8	82
68	First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. <i>ESMO Open</i> , 2020, 5, e001110.	2.0	42
69	Pregnancy in Women with Metastatic Sarcomas. <i>Oncologist</i> , 2020, 25, e2010-e2012.	1.9	2
70	Long term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). <i>PLoS ONE</i> , 2020, 15, e0233046.	1.1	8
71	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2020, 87, 102040.	3.4	35
72	Rare ovarian tumors: an update on diagnosis and treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 879-887.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Cabozantinib as an emerging treatment for sarcoma. <i>Current Opinion in Oncology</i> , 2020, 32, 321-331.	1.1	14
74	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
75	Incidence and time trends of sarcoma (2000â€“2013): results from the French network of cancer registries (FRANCIM). <i>BMC Cancer</i> , 2020, 20, 190.	1.1	31
76	CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4625-4632.	3.2	47
77	The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study. <i>Gynecologic Oncology</i> , 2020, 157, 78-84.	0.6	10
78	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a firstâ€“line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
79	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 446-455.	5.1	182
80	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , 2020, 156, 715-725.	0.6	74
81	Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1818-1827.	0.7	28
82	Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group. <i>Gynecologic Oncology</i> , 2020, 157, 29-35.	0.6	24
83	Clinical management of adolescents and young adults suffering from sarcoma in the French RhÃ“ne-Alpes region: A prospective exhaustive cohort with 10 years follow up. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1301-1309.	0.5	5
84	Rare Gynecologic Tumors: Coming of Age. <i>Gynecologic Oncology</i> , 2020, 157, 1-2.	0.6	2
85	Small-Cell Carcinoma of the Ovary, Hypercalcemic Typeâ€“Genetics, New Treatment Targets, and Current Management Guidelines. <i>Clinical Cancer Research</i> , 2020, 26, 3908-3917.	3.2	82
86	First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. <i>ESMO Open</i> , 2020, 5, e001075.	2.0	14
87	A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin Â± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1633-1637.	1.2	4
88	Beyond the map: evidencing the spatial dimension of health inequalities. <i>International Journal of Health Geographics</i> , 2020, 19, 46.	1.2	28
89	Management of Rare Uterine Malignant Tumors. , 2020, , 277-312.		0
90	ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based caseâ€“control studyâ€“study protocol. <i>BMJ Open</i> , 2019, 9, e030013.	0.8	8

#	ARTICLE	IF	CITATIONS
91	Management of Rare Ovarian Cancer Histologies. <i>Journal of Clinical Oncology</i> , 2019, 37, 2406-2415.	0.8	19
92	Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. <i>Future Oncology</i> , 2019, 15, 2139-2149.	1.1	2
93	Pazopanib or methotrexate+vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1263-1272.	5.1	123
94	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProFiLER programme. <i>European Journal of Cancer</i> , 2019, 118, 156-165.	1.3	11
95	Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. <i>Gynecologic Oncology</i> , 2019, 155, 262-269.	0.6	19
96	Systemic (chemo)therapies for Rare Gynecological Malignancies. <i>Annals of Oncology</i> , 2019, 30, vi50.	0.6	0
97	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832.	1.3	23
98	Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. <i>European Journal of Cancer</i> , 2019, 116, 35-44.	1.3	25
99	Very long-term survivors among patients with metastatic soft tissue sarcoma. <i>Cancer Medicine</i> , 2019, 8, 1368-1378.	1.3	16
100	Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. <i>International Journal of Cancer</i> , 2019, 145, 2135-2143.	2.3	10
101	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. <i>Clinical Cancer Research</i> , 2019, 25, 5342-5350.	3.2	33
102	Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 85-94.	1.4	20
103	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019, 24, e536-e541.	1.9	26
104	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	13.9	1,176
105	Current role of poly(ADP-ribose) polymerase inhibitors. <i>Current Opinion in Oncology</i> , 2019, 31, 394-403.	1.1	2
106	Sexual desire of French representative prostate cancer survivors 2 years after diagnosis (the VICAN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	5
107	Non-pegylated liposomal doxorubicin (NPLD, Myocet®)+carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial. <i>Gynecologic Oncology</i> , 2019, 152, 68-75.	0.6	4
108	BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	7.7	278

#	ARTICLE	IF	CITATIONS
109	Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, e183773.	3.4	60
110	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 67-74.	0.5	22
111	Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1094-1100.	0.6	9
112	A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. <i>Personalized Medicine</i> , 2018, 15, 13-24.	0.8	0
113	Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. <i>Acta Neuropathologica</i> , 2018, 135, 569-579.	3.9	73
114	Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 326-333.	3.2	40
115	High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 221, 40-45.	0.5	20
116	Geographical Accessibility of the Sarcoma Referral Networks in France. Intermediate Results from the IGACAS Research Program. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2204.	1.2	20
117	Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2018, 23, 948-955.	1.9	18
118	The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. <i>PLoS ONE</i> , 2018, 13, e0193330.	1.1	38
119	Management of relapsed ovarian cancer in routine clinical practice: a case study. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 9-11.	1.1	2
120	Gynecological sarcomas: what's new in 2018, a brief review of published literature. <i>Current Opinion in Oncology</i> , 2018, 30, 246-251.	1.1	10
121	Options for treating different soft tissue sarcoma subtypes. <i>Future Oncology</i> , 2018, 14, 25-49.	1.1	35
122	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , 2018, 7, 4023-4035.	1.3	39
123	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. <i>British Journal of Cancer</i> , 2017, 116, 1505-1512.	2.9	25
124	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2017, 18, 75-87.	5.1	975
125	Improving treatment results with reference centres for Rare cancers: where do we stand?. <i>European Journal of Cancer</i> , 2017, 77, 90-98.	1.3	44
126	Evolving biological understanding and treatment of sarcomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 78-80.	12.5	12

#	ARTICLE	IF	CITATIONS
127	Trabectedin mechanism of action and platinum resistance: molecular rationale. <i>Future Oncology</i> , 2017, 13, 17-21.	1.1	12
128	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	0.8	76
129	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	0.6	222
130	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	5.1	1,376
131	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1089-1103.	5.1	214
132	Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS). <i>BMC Cancer</i> , 2017, 17, 111.	1.1	11
133	European Journal of Cancer™s Biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas. <i>European Journal of Cancer</i> , 2017, 70, 83-86.	1.3	5
134	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 1787-1797.	2.9	30
135	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. <i>Journal of Onco-Nephrology</i> , 2017, 1, 213-219.	0.3	0
136	Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	67
137	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4345-4353.	0.8	68
138	DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study. <i>Histopathology</i> , 2016, 68, 279-285.	1.6	82
139	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 632-641.	5.1	98
140	Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. <i>Gynecologic Oncology</i> , 2016, 142, 95-101.	0.6	14
141	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. <i>European Journal of Cancer</i> , 2016, 58, 90-96.	1.3	111
142	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. <i>Oncology Letters</i> , 2016, 11, 1859-1865.	0.8	8
143	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology</i> , The, 2016, 17, 1261-1271.	5.1	161
144	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34.	0.6	81

#	ARTICLE	IF	CITATIONS
145	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1732-1742.	5.1	200
146	Cutaneous lesions in sporadic angiosarcomas of the breast: a misleading presentation. <i>European Journal of Dermatology</i> , 2016, 26, 287-289.	0.3	1
147	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89.	5.1	205
148	The value of research collaborations and consortia in rare cancers. <i>Lancet Oncology</i> , The, 2016, 17, e62-e69.	5.1	89
149	Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. <i>Gynecologic Oncology</i> , 2016, 140, 457-462.	0.6	159
150	Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTCâ€™S (Observatoire de lâ€™Utilisation des ThÃ©rapies CiblÃ©es dans les Sarcomes). <i>BMC Cancer</i> , 2015, 15, 854.	1.1	25
151	KIT exon 10 variant (c.1621 Aâ€™>â€™C) single nucleotide polymorphism as predictor of GIST patient outcome. <i>BMC Cancer</i> , 2015, 15, 780.	1.1	13
152	Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015, 51, 742-750.	1.3	86
153	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 312-319.	5.1	78
154	Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. <i>Targeted Oncology</i> , 2015, 10, 583-596.	1.7	23
155	Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 60-65.	1.1	27
156	17Î²-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. <i>Carcinogenesis</i> , 2015, 36, 564-573.	1.3	38
157	ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. <i>Annals of Oncology</i> , 2015, 26, 1353-1362.	0.6	63
158	New clinical research strategies for rare gynecologic malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 53-57.	0.9	7
159	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. <i>Oncotarget</i> , 2015, 6, 26388-26399.	0.8	9
160	Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study. <i>Blood</i> , 2015, 126, 3363-3363.	0.6	0
161	Treatment of Chemotherapy-Induced Anemia Using Epoetin Alfa Biosimilar for Patients with Lymphoma and Myeloma: The Synergy Study. <i>Blood</i> , 2015, 126, 952-952.	0.6	0
162	Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the RhÃˆne-Alpes region. <i>International Journal of Clinical Oncology</i> , 2014, 19, 744-52.	1.0	32

#	ARTICLE	IF	CITATIONS
163	The off-label use of targeted therapies in sarcomas: the OUTCâ€™S program. BMC Cancer, 2014, 14, 870.	1.1	20
164	A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 2192-2204.	3.2	147
165	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research, 2014, 20, 6105-6116.	3.2	129
166	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Uterine and Ovarian Carcinosarcoma. International Journal of Gynecological Cancer, 2014, 24, S55-S60.	1.2	113
167	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian Sex Cord Stromal Tumors. International Journal of Gynecological Cancer, 2014, 24, S42-S47.	1.2	74
168	The clinicianâ€™s perspective on sarcoma pathology reporting: impact on treatment decisions?. Pathology, 2014, 46, 121-125.	0.3	7
169	Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer. Obstetrical and Gynecological Survey, 2014, 69, 402-404.	0.2	19
170	Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Targeted Oncology, 2014, 9, 273-277.	1.7	23
171	Intravenous aflibercept in patients with platinumâ€™resistant, advanced ovarian cancer: Results of a randomized, doubleâ€™blind, phase 2, parallelâ€™arm study. Cancer, 2014, 120, 335-343.	2.0	49
172	Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin. Cancer Treatment Reviews, 2014, 40, 366-375.	3.4	58
173	Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 207-216.	2.0	154
174	High-Grade Undifferentiated Sarcomas of the Uterus: Diagnosis, Outcomes, and New Treatment Approaches. Current Oncology Reports, 2014, 16, 405.	1.8	15
175	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 799-808.	5.1	279
176	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. Journal of Clinical Oncology, 2014, 32, 3374-3382.	0.8	302
177	Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. Journal of Clinical Oncology, 2014, 32, 1302-1308.	0.8	1,240
178	Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Gynecologic Oncology, 2014, 132, 181-187.	0.6	24
179	Outcome of patients with advanced solitary fibrous tumors: the Centre LÃ©on BÃ©nard experience. BMC Cancer, 2013, 13, 109.	1.1	62
180	A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Supportive Care in Cancer, 2013, 21, 1947-1954.	1.0	9

#	ARTICLE	IF	CITATIONS
181	Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. <i>Targeted Oncology</i> , 2013, 8, 261-269.	1.7	10
182	Sorafenib in patients with progressive epithelioid hemangioendothelioma. <i>Cancer</i> , 2013, 119, 2639-2644.	2.0	97
183	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. <i>Gynecologic Oncology</i> , 2013, 130, 25-30.	0.6	79
184	Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. <i>Targeted Oncology</i> , 2013, 8, 243-251.	1.7	44
185	Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. <i>British Journal of Cancer</i> , 2013, 108, 1771-1777.	2.9	100
186	Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2485-2492.	0.8	213
187	Primary Ovarian Borderline Tumor in the Inguinal Lymph Node. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 167-170.	0.9	5
188	Biology of ovarian cancer and trabectedin mechanism of action. <i>Future Oncology</i> , 2013, 9, 11-17.	1.1	8
189	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1BA5503-1BA5503.	0.8	35
190	Do Our Current Clinical Trial Designs Help to Guide Clinical Practice?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e381-e385.	1.8	0
191	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2012, 17, 260-266.	1.9	170
192	Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2718-2724.	0.8	630
193	Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. <i>Oncolmmunology</i> , 2012, 1, 380-382.	2.1	114
194	Mechanisms of resistance to endocrine therapies for breast cancer. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2012, 9, 165-171.	0.3	0
195	Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. <i>Annals of Oncology</i> , 2012, 23, 2442-2449.	0.6	179
196	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. <i>Oncolmmunology</i> , 2012, 1, 432-440.	2.1	102
197	Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2012, 127, 63-69.	0.6	128
198	Pazopanib for soft-tissue sarcoma: a PALETTE of data emerges. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 431-432.	12.5	7

#	ARTICLE	IF	CITATIONS
199	A role for maintenance therapy in managing sarcoma. <i>Cancer Treatment Reviews</i> , 2012, 38, 368-378.	3.4	17
200	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncology</i> , 2012, 13, 1133-1140.	5.1	490
201	Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization. <i>Bulletin Du Cancer</i> , 2012, 99, E34-E42.	0.6	16
202	First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. <i>Bulletin Du Cancer</i> , 2012, 99, E18-E25.	0.6	3
203	Pazopanib for the treatment of soft-tissue sarcoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2012, 4, 65.	0.8	14
204	Incidence of soft tissue sarcoma and beyond. <i>Cancer</i> , 2012, 118, 5339-5348.	2.0	210
205	Management of Anemia in Advanced Breast and Lung Cancer Patients in Daily Practice: Results of a French Survey. <i>Advances in Therapy</i> , 2012, 29, 124-133.	1.3	14
206	PI3 kinase inhibitors in the clinic: an update. <i>Anticancer Research</i> , 2012, 32, 2463-70.	0.5	48
207	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 5423-5434.	0.4	200
208	Therapeutic pipeline for soft-tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2479-2491.	0.9	9
209	Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial. <i>Gynecologic Oncology</i> , 2011, 122, 226-232.	0.6	59
210	Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 187-195. ^{1.1}		10
211	<i>ERCC5</i> , <i>XPG</i> , <i>ERCC1</i> and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. <i>Cancer</i> , 2011, 117, 3445-3456.	2.0	57
212	Combination therapy for gastrointestinal stromal tumors: evidence from recent clinical trials. <i>Clinical Investigation</i> , 2011, 1, 825-836.	0.0	1
213	Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing. <i>PLoS ONE</i> , 2011, 6, e20294.	1.1	428
214	Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. <i>Anti-Cancer Drugs</i> , 2010, 21, 113-119.	0.7	27
215	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 745-753.	1.1	41
216	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , 2010, 28, 76-82.	1.2	26

#	ARTICLE	IF	CITATIONS
217	Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. <i>BMC Cancer</i> , 2010, 10, 150.	1.1	78
218	Management of rare ovarian cancers: The experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: Interim analysis of the first 100 patients. <i>Gynecologic Oncology</i> , 2010, 119, 53-59.	0.6	35
219	Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1733-1739.	0.8	158
220	Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 942-949.	5.1	260
221	New developments in treatment of ovarian carcinoma: focus on trabectedin. <i>Cancer Management and Research</i> , 2010, 2, 233-42.	0.9	0
222	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer "Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). <i>Journal of Clinical Oncology</i> , 2009, 27, 3126-3132.	0.8	611
223	Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. <i>Cancer Research</i> , 2009, 69, 5383-5391.	0.4	610
224	A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 5910-5916.	3.2	101
225	Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series. <i>Clinical Breast Cancer</i> , 2009, 9, 118-121.	1.1	58
226	Drug Management of Prostate Cancer: Prevalence and Consequences of Renal Insufficiency. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E83-E89.	0.9	23
227	Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. <i>Cancer</i> , 2009, 115, 1234-1244.	2.0	1,270
228	Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues. <i>Lung</i> , 2009, 187, 69-74.	1.4	40
229	2007 Standards, Options, and Recommendations: Use of erythropoiesis-stimulating agents (ESA: epoetin) Tj ETQq1 1 0.784314 rgB Blood and Cancer, 2009, 53, 7-12.	0.8	16
230	Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 124-133.	2.0	45
231	Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. <i>Cancer Research</i> , 2009, 69, 2000-2009.	0.4	617
232	Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. <i>Lancet</i> , The, 2009, 373, 1532-1542.	6.3	546
233	Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?. <i>Current Opinion in Oncology</i> , 2009, 21, 360-366.	1.1	11
234	Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients. <i>PLoS ONE</i> , 2009, 4, e6483.	1.1	14

#	ARTICLE	IF	CITATIONS
235	Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. <i>Current Gastroenterology Reports</i> , 2008, 10, 555-561.	1.1	10
236	A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. <i>Cancer</i> , 2008, 113, 2532-2538.	2.0	22
237	Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5269-5274.	0.8	569
238	A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. <i>Oncologist</i> , 2008, 13, 467-473.	1.9	53
239	Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2008, 14, 6656-6662.	3.2	73
240	Imatinib mesilate for the treatment of gastrointestinal stromal tumour. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1211-1222.	0.9	19
241	ET-743: a novel agent with activity in soft-tissue sarcomas. <i>Current Opinion in Oncology</i> , 2006, 18, 347-353.	1.1	53
242	Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. <i>International Journal of Cancer</i> , 2006, 119, 706-711.	2.3	169
243	Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer/Italian Sarcoma Group/Australasian Gastrointestinal Trials Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5795-5804.	0.8	266
244	ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas. <i>Oncologist</i> , 2005, 10, 827-832.	1.9	38
245	Lymphopenia: A new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. <i>Radiotherapy and Oncology</i> , 2005, 76, 334-339.	0.3	56
246	Persistence of Medical Change at Implementation of Clinical Guidelines on Medical Practice: A Controlled Study in a Cancer Network. <i>Journal of Clinical Oncology</i> , 2005, 23, 4414-4423.	0.8	53
247	Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7466-7474.	3.2	399
248	Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. <i>Gynecologic Oncology</i> , 2003, 88, 351-357.	0.6	7
249	Risk Model Predictive of Severe Anemia Requiring RBC Transfusion After Chemotherapy in Pediatric Solid Tumor Patients. <i>Journal of Clinical Oncology</i> , 2003, 21, 4235-4238.	0.8	17
250	BCG Therapy-related Death and Previous Pelvic Radiation. <i>Annals of Pharmacotherapy</i> , 2001, 35, 963-964.	0.9	3